Article
Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas.
Science translational medicine - 6 Jul 2022
Menghi Francesca, Banda Kalyan, Kumar Pooja, Straub Robert, Dobrolecki Lacey, Rodriguez Isabel V, Yost Susan E, Chandok Harshpreet, Radke Marc R, Somlo George, Yuan Yuan, Lewis Michael T, Swisher Elizabeth M, Liu Edison T
Abstract excerpt
Triple-negative breast cancer (TNBC) and ovarian carcinomas (OvCas) with BRCA1 promoter methylation (BRCA1meth) respond more poorly to alkylating agents compared to those bearing mutations in BRCA1 and BRCA2 (BRCAmut). This is a conundrum given the biologically equivalent homologous recombination deficiency (HRD) induced by these genetic and epigenetic BRCA perturbations. We dissected this problem through...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.